Daily Endocrinology Research Analysis
Three mechanistic studies reshape endocrine biology and therapeutic directions: an adipocyte-secreted kinase (FAM20C) is identified as an early driver of obesity-induced inflammation and insulin resistance; EZH2-mediated epigenetic repression in anaplastic thyroid cancer is shown to be reversible, restoring iodide uptake; and loss of lysosomal cholesterol transporter NPC1 is linked to aldosterone overproduction via dual mitochondrial and Ca2+ signaling pathways.
Summary
Three mechanistic studies reshape endocrine biology and therapeutic directions: an adipocyte-secreted kinase (FAM20C) is identified as an early driver of obesity-induced inflammation and insulin resistance; EZH2-mediated epigenetic repression in anaplastic thyroid cancer is shown to be reversible, restoring iodide uptake; and loss of lysosomal cholesterol transporter NPC1 is linked to aldosterone overproduction via dual mitochondrial and Ca2+ signaling pathways.
Research Themes
- Adipose tissue–immune crosstalk driving systemic insulin resistance
- Epigenetic re-differentiation strategies to restore endocrine function in cancer
- Intracellular cholesterol trafficking as a regulator of steroidogenesis
Selected Articles
1. Secretory kinase FAM20C triggers adipocyte dysfunction inciting insulin resistance and inflammation in obesity.
This mechanistic study identifies FAM20C as an obesity-induced adipocyte kinase that drives proinflammatory signaling and insulin resistance; adipocyte-specific loss of Fam20c after obesity improves glucose tolerance and insulin sensitivity without affecting body weight. Phosphoproteomics reveals intracellular and secreted substrates (e.g., CNPY4) linking FAM20C activity to inflammation, metabolism, and ECM remodeling, and human visceral adipose FAM20C correlates with insulin resistance.
Impact: Reveals a previously unrecognized kinase node in adipocytes that causally links obesity to systemic insulin resistance and inflammation, offering a druggable target for T2D.
Clinical Implications: FAM20C inhibition could represent a new therapeutic strategy to restore adipocyte health and insulin sensitivity in obesity/T2D; adipose FAM20C expression might serve as a biomarker of adipose inflammatory dysfunction.
Key Findings
- FAM20C expression is markedly upregulated in adipocytes in obesity and correlates with a proinflammatory transcriptional signature.
- Adipocyte Fam20c overexpression induces cytokines and insulin resistance in a kinase-dependent manner; adipocyte-specific deletion after established obesity improves glucose tolerance and insulin sensitivity and reduces visceral adiposity.
- Phosphoproteomics identifies intracellular and secreted substrates (e.g., CNPY4) mediating inflammation, metabolism, and ECM remodeling.
- In human visceral fat, FAM20C expression positively correlates with insulin resistance.
Methodological Strengths
- Integrated in vivo loss-of-function with gain-of-function models and phosphoproteomics.
- Human translational correlation using visceral adipose tissue expression and metabolic phenotypes.
Limitations
- Preclinical models; no in vivo pharmacologic FAM20C inhibitor tested.
- Long-term safety and off-target effects of FAM20C modulation remain unknown.
Future Directions: Develop selective FAM20C inhibitors/biologics; test metabolic efficacy and safety in obese/T2D models and early-phase human trials; validate circulating or tissue biomarkers of FAM20C activity.
Obesity is a major driver of type 2 diabetes (T2D) and related metabolic disorders, characterized by chronic inflammation and adipocyte dysfunction. However, the molecular triggers initiating these processes remain poorly understood. We identify FAM20C, a serine/threonine kinase, as an early obesity-induced mediator of adipocyte dysfunction. Fam20c expression is substantially upregulated in adipocytes in response to obesity, correlating with a proinflammatory transcriptional signature. Forced expression of Fam20c in adipo
2. Inhibition of NPC Intracellular Cholesterol Transporter 1 Dually Regulates Aldosterone Secretion Via the Steroidogenic Acute Regulatory-Related Lipid Transfer Domain-3-Voltage-Dependent Anion Channel 1 Axis and Inositol 1,4,5-Trisphosphate Receptor Type 3-Calcium Signaling.
Quantitative proteomics and functional assays show that NPC1 is downregulated in aldosterone-producing adenomas and that NPC1 inhibition increases aldosterone secretion by two mechanisms: enhanced lysosome–mitochondria cholesterol transfer via STARD3–VDAC1 causing mitochondrial cholesterol overload, and IP3R3-dependent ER Ca2+ release upregulating CYP11B2.
Impact: Defines a new cholesterol-trafficking and Ca2+ signaling mechanism for aldosterone excess, opening avenues to target lysosome–mitochondria contact sites or IP3R3 in primary aldosteronism.
Clinical Implications: NPC1 pathway components (STARD3–VDAC1, IP3R3) may represent drug targets to reduce aldosterone synthesis in aldosterone-producing adenomas; NPC1 status could inform stratification or predict responsiveness to agents modulating cholesterol trafficking or Ca2+ signaling.
Key Findings
- NPC1 is significantly downregulated in human aldosterone-producing adenoma tissues by quantitative proteomics.
- NPC1 inhibition increases aldosterone secretion in H295R cells.
- Mechanisms include STARD3–VDAC1–mediated lysosome–mitochondria tethering leading to mitochondrial cholesterol overload and IP3R3-dependent ER Ca2+ release increasing aldosterone synthase (CYP11B2).
Methodological Strengths
- Combines discovery proteomics with targeted functional validation (immunofluorescence, co-IP, Ca2+ measurements).
- Uses a human steroidogenic cell model (H295R) and human tumor tissue analyses.
Limitations
- Predominantly in vitro; no in vivo validation of NPC1 targeting in animal models.
- Therapeutic tractability and safety of modulating lysosome–mitochondria contacts or IP3R3 in adrenal tissue remain to be established.
Future Directions: Validate findings in vivo; assess pharmacologic modulators of STARD3–VDAC1 or IP3R3 in preclinical models; explore NPC1 expression as a biomarker for primary aldosteronism subtyping.
BACKGROUND: Aldosterone-producing adenomas, a prevalent cause of endocrine hypertension, arise from uncontrolled aldosterone production. NPC1 (NPC intracellular cholesterol transporter 1) is a cholesterol transporter located on the lysosomal limiting membrane. Although cholesterol serves as the primary precursor for aldosterone synthesis, the mechanism governing its supply and metabolism within aldosterone-producing adenomas remains unclear. METHODS: In this study, we used quantitative proteomics and observed that NPC1 was significantly downregulated in aldosterone-producing adenoma tissues. RESULTS: Liquid chromatography/tandem mass spectrometry analysis found that inhibition of NPC1 increased aldosterone secretion in H295R cells. Mechanistically, NPC1 deficiency promoted aldosterone production through 2 pathways: (1) immunofluorescence and coimmunoprecipitation experiments confirmed that NPC1 deficiency enhanced lysosome-mitochondria interaction via STARD3-VDAC1 (steroidogenic acute regulatory-related lipid transfer domain-3-voltage-dependent anion channel 1), leading to mitochondrial cholesterol overload; and (2) Western Blot and calcium measurement showed that NPC1 deficiency activated of cytoplasmic calcium signaling through IP3R3 (inositol 1,4,5-trisphosphate receptor type 3)-mediated endoplasmic reticulum calcium release, resulting in upregulated expression of aldosterone synthase. CONCLUSIONS: Our findings demonstrate that NPC1 downregulation represents a novel mechanism driving elevated aldosterone production, linking lysosomal-mitochondria cholesterol transport to aldosterone high production. These results suggest that NPC1 may offer a new understanding for aldosterone overproduction mechanism of aldosterone-producing adenomas.
3. Targeting EZH2 reverses thyroid cell dedifferentiation and enhances iodide uptake in anaplastic thyroid cancer.
Epigenomic profiling and functional assays demonstrate that EZH2/H3K27me3 repress thyroid differentiation genes in ATC; the EZH2 inhibitor EPZ6438 (tazemetostat) reactivates differentiation programs and partially restores iodide uptake, further enhanced by MEK inhibition, suggesting a rational combination to re-sensitize ATC to radioiodine.
Impact: Provides a mechanistic basis and immediate repurposing path for an FDA-approved EZH2 inhibitor to enhance radioiodine therapy in an otherwise refractory, lethal endocrine cancer.
Clinical Implications: Supports clinical trials of tazemetostat with or without MEK inhibitors to re-differentiate ATC and restore radioiodine sensitivity; suggests epigenetic profiling (EZH2/H3K27me3 at TDGs) as a predictive biomarker.
Key Findings
- EZH2/H3K27me3 is enriched at key thyroid differentiation genes (SLC5A5, NKX2-1, TSHR, FOXE1, TPO) in ATC cells.
- Pharmacologic EZH2 inhibition (EPZ6438/tazemetostat) reactivates thyroid differentiation gene expression and partially restores iodide uptake across RAS- and BRAF-mutant ATC lines.
- MEK1/2 inhibitor co-treatment further enhances differentiation gene expression, consistent with MAPK-dependent EZH2 regulation.
Methodological Strengths
- Orthogonal epigenomic assays (public ChIP-seq, CUT&RUN) corroborated with pharmacologic perturbation.
- Demonstrated effects across distinct oncogenotypes (RAS and BRAF).
Limitations
- Data are limited to in vitro cell line models; no in vivo validation.
- Iodide uptake restoration was partial; durability and radiosensitization in vivo remain unknown.
Future Directions: Evaluate tazemetostat ± MEK inhibition in ATC xenografts and early-phase trials; define dosing/sequencing to maximize re-differentiation; develop biomarkers (H3K27me3 at TDGs) for patient selection.
Anaplastic thyroid carcinoma (ATC) is a highly aggressive malignancy characterized by dedifferentiation and radioiodine refractoriness. We investigated whether EZH2-mediated H3K27me3 deposition represses thyroid differentiation genes (TDGs) in ATC cells. Online ChIP-seq analyses and CUT&RUN confirmed EZH2/H3K27me3 enrichment at key TDGs (SLC5A5, NKX2-1, TSHR, FOXE1, TPO). Pharmacological inhibition of EZH2 with EPZ6438 reactivated TDG expression in RAS and BRAF-mutated ATC cell lines and partially restored iodide uptake. Co-treatment with the MEK1/2 inhibitor U0126 further enhanced TDG expression, consistent with MAPK-dependent regulation of EZH2. These findings reveal EZH2 as a mediator of ATC dedifferentiation and highlight its inhibition as a potential strategy to restore thyroid function and sensitize tumors to radioiodine. Impact statement This study reveals how EZH2-driven epigenetic remodeling controls thyroid cell dedifferentiation and loss of iodide uptake in anaplastic thyroid cancer. Our findings provide new mechanistic insights and highlight an FDA-approved drug with repurposing potential, advancing both anaplastic thyroid cancer biology research and therapeutic perspectives.